@Noobie123. Okay. Sorry

@Noobie123. I intended to stress that it is an agreement, not MOU.

yingzhe17 Duopharma is only packing. Distributor will be Kanger. Wait for press release.
--------------------
Hope to see that you have a reliable source of information. Thanks.

Noobie123 1. MOU is not an agreement. It is just a letter to state understandings.
----------------------------------

The distributorship agreement has been signed by Kanger and Sinopharm Group Hunan Changde Medical Co Ltd. Instead, its not an MOU.
.........
2. Kanger has entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.

Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia, however, both parties will sign a separate agreement in regards to specific product category, price, purchase price and payment method.

(Remarks: This agreement shall take effect for a period of three years effective from 25 September 2020 until 24 September 2023)

Source: https://www.msn.com/en-my/news/national/kanger-sinopharm-inks-agreement-for-covid-19-vaccine-distribution-in-malaysia/ar-BB19x0Lr

TEKNIK HARAPAN.... He He

I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not. Just curious about the report given by KJ, on .... SOME COMPANIES

..... I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China.

By the way, the RI theme is underway. @Fong Kh. I beg to differ.

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

...... The immunisation programme now has a total of six vaccines within its portfolio: Sinopharm, Pfizer-BioNTech, AstraZeneca, Sinovac, Cansino, and Johnson & Johnson.

Cuma timbul persoalan. Adakah bekalan untuk swasta dan kerajaan negeri semuanya mesti dibekalkan melalui GLC yang dilantik? Bagaimana dengan permohohan untuk kelulusan sinopharm dari pihak lain selain daripada Duopharma. Adakah ditolak sepenuhnya????

@Noobie123.

The predictions only been made by a reference to the news. I'm not insider nor political agent. He He

Report 5: 24 June 2021.
“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

@18KHarmoni. I am good. Portfolio getting better. I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not.

By the way, the RI theme is underway. The vaccine plan is a bonus as been said before by a number of us....
INVESTING IS PLAYING A RISKY GAME. He He.

Pharma dan Duopharma down. Ini mesti ada udang sebalik batu.
Takkan Kanger tak boleh gap up sikit kot. He He

Yes....

@BilisMasin. Khusus untuk Zuelig.

1. Perjanjian sebagai DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107

2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE

Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia.

3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE

Sumber:

1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

SEKARANG TUNGGU UNTUK PROSES UMUM SAHAJA FASAL APPROVAL OLEH NPRA SAHAJA.

Dr Noor Hisham: NPRA set to announce Sinopharm’s inclusion in Covid-19 immunisation plan

“Tomorrow the NPRA will meet and we will consider the Sinopharm vaccine, which was approved by the World Health Organisation.

“Their company just sent their dossiers to us, and in less than a month we have evaluated and will give our decision on the conditional approval tomorrow,” he said.

Source: https://malaysia.news.yahoo.com/dr-noor-hisham-npra-set-111805262.html

Dr Noor Hisham: NPRA set to announce Sinopharm’s inclusion in Covid-19 immunisation plan

“Tomorrow the NPRA will meet and we will consider the Sinopharm vaccine, which was approved by the World Health Organisation.

“Their company just sent their dossiers to us, and in less than a month we have evaluated and will give our decision on the conditional approval tomorrow,” he said.

Source: https://malaysia.news.yahoo.com/dr-noor-hisham-npra-set-111805262.html

@Luckybull. Noted. Thanks.

Dr Noor Hisham: NPRA set to announce Sinopharm’s inclusion in Covid-19 immunisation plan

“Tomorrow the NPRA will meet and we will consider the Sinopharm vaccine, which was approved by the World Health Organisation.

“Their company just sent their dossiers to us, and in less than a month we have evaluated and will give our decision on the conditional approval tomorrow,” he said.
Source: https://malaysia.news.yahoo.com/dr-noor-hisham-npra-set-111805262.html

https://www.theedgemarkets.com/article/nexgrams-quarantine-management-system-inbound-travellers-officially-online

Tracvirus E-Cert Digital Health Records
SafeTravelPass allow travellers to digitalise Covid-19 test and vaccine records on their mobile phone for personal use, and is officially recognised by Malaysia government system TracAPM to facilitate international travelling references.
The travel passport made possible with the embedded Tracvirus E-Cert. Travellers Covid-19 tests or vaccination records registered with Tracvirus Depository will be unified under Tracvirus E-Cert which is recognised by STP QR Code for International travelling.
Tracvirus E-Cert is certified OnepassWorld (OPW) compliance, ready for individuals’ digital access to their health data under unified standard recognised worldwide. OPW support HL7 and FHIR global standard for health care data exchange.
Government and private laboratories can apply as Tracvirus Lab Partners at https://tracvirus.com to register lab test reports and vaccine records with Tracvirus E-Cert and officially recognised by government system TracAPM for International travelling. Hospitals and clinics can apply as Tracvirus Panel Clinics attached to your local laboratories.

Tracvirus E-Cert Digital Health Records
SafeTravelPass allow travellers to digitalise Covid-19 test and vaccine records on their mobile phone for personal use, and is officially recognised by Malaysia government system TracAPM to facilitate international travelling references.
The travel passport made possible with the embedded Tracvirus E-Cert. Travellers Covid-19 tests or vaccination records registered with Tracvirus Depository will be unified under Tracvirus E-Cert which is recognised by STP QR Code for International travelling.
Tracvirus E-Cert is certified OnepassWorld (OPW) compliance, ready for individuals’ digital access to their health data under unified standard recognised worldwide. OPW support HL7 and FHIR global standard for health care data exchange.
Government and private laboratories can apply as Tracvirus Lab Partners at https://tracvirus.com to register lab test reports and vaccine records with Tracvirus E-Cert and officially recognised by government system TracAPM for International travelling. Hospitals and clinics can apply as Tracvirus Panel Clinics attached to your local laboratories.

Government of Malaysia Acceptance and Commissioning of TracAPM, SafeTravelPass and MyABC19 as the official government systems [14 July 2021]

“TracAPM” digitalisation system is today officially accepted and commissioned by the government of Malaysia for civil defence digitalisation. Current services include travellers quarantine management in all International borders (Pintu Masuk Antarabangsa “PMA”), quarantine station management, and quarantine transport management.

TracAPM official travel pass SafeTravelPass provides Covid-19 quarantine entry-registration and quarantine station payment for all travellers coming into Malaysia.

The system is developed for the government of Malaysia, licensed and maintained by Tri-G Technologies Sdn Bhd, the sister company of Nexgram Biomedic Sdn Bhd, both subsidiaries of Nexgram Holdings Berhad (“company”).

Source 1: https://tracapm.com/2021/07/15/government-of-malaysia-acceptance-and-commissioning-of-tracapm-safetravelpass-and-myabc19-as-the-official-government-systems-14-july-2021/

Source 2: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3175499

Government of Malaysia Acceptance and Commissioning of TracAPM, SafeTravelPass and MyABC19 as the official government systems [14 July 2021]

“TracAPM” digitalisation system is today officially accepted and commissioned by the government of Malaysia for civil defence digitalisation. Current services include travellers quarantine management in all International borders (Pintu Masuk Antarabangsa “PMA”), quarantine station management, and quarantine transport management.

TracAPM official travel pass SafeTravelPass provides Covid-19 quarantine entry-registration and quarantine station payment for all travellers coming into Malaysia.

The system is developed for the government of Malaysia, licensed and maintained by Tri-G Technologies Sdn Bhd, the sister company of Nexgram Biomedic Sdn Bhd, both subsidiaries of Nexgram Holdings Berhad (“company”).

Source 1: https://tracapm.com/2021/07/15/government-of-malaysia-acceptance-and-commissioning-of-tracapm-safetravelpass-and-myabc19-as-the-official-government-systems-14-july-2021/

Source 2: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3175499

Sekarang sistem TracAPM - SafeTravelPass dan direcognize oleh kerajaan sebagai sistem rasmi. Sistem lain termasuk oleh MYEG akan jadi sistem pilihan.

OKU_2020 recycled cerita lama @dah basii dahh Beb
--------------------
Cerita baru lah. Updated 15/7/2021

Tracvirus E-Cert Digital Health Records
SafeTravelPass allow travellers to digitalise Covid-19 test and vaccine records on their mobile phone for personal use, and is officially recognised by Malaysia government system TracAPM to facilitate international travelling references.
The travel passport made possible with the embedded Tracvirus E-Cert. Travellers Covid-19 tests or vaccination records registered with Tracvirus Depository will be unified under Tracvirus E-Cert which is recognised by STP QR Code for International travelling.
Tracvirus E-Cert is certified OnepassWorld (OPW) compliance, ready for individuals’ digital access to their health data under unified standard recognised worldwide. OPW support HL7 and FHIR global standard for health care data exchange.
Government and private laboratories can apply as Tracvirus Lab Partners at https://tracvirus.com to register lab test reports and vaccine records with Tracvirus E-Cert and officially recognised by government system TracAPM for International travelling. Hospitals and clinics can apply as Tracvirus Panel Clinics attached to your local laboratories.

After a slow start, a quarter of the population has now received at least one dose and Malaysia’s target of having 40 per cent of adults fully vaccinated by the end of August and 60 per cent by the end of September could be achieved if suppliers meet their commitments.

Source: https://www.smh.com.au/world/asia/crushed-by-covid-malaysia-now-has-one-of-the-world-s-fastest-vaccination-rates-20210714-p589k4.html

Status Vaksinasi di Malaysia
Info dikemaskini pada 13 Julai 2021
Sumber: Kementerian Kesihatan Malaysia

VAKSIN DOS 1
+251,575
8,355,643

VAKSIN DOS 2
+164,252
3,848,373

ADAR PEMBERIAN DOS VAKSIN COVID-19 BERBANDING POPULASI MALAYSIA
Setakat 14 Julai 2021

Dos 1 25.6 %
Dos 2 11.8%

Source: https://www.astroawani.com/berita-malaysia/covid19-data-dan-informasi-setakat-ini-dikemas-kini-setiap-hari-250959

@wistlebower99.

DO YOU HAVE ANY COMMENT ABOUT THESE PLANS BY KANGER?
PLEASE BE OBJECTIVE ABOUT IT. IF YOU CAN, PLEASE GIVE ANY PRO OR CON ABOUT THE COMPANY'S PLANS OF DEVELOPMENT.....

Kanger is still in progressing state in its current business, which are a bamboo flooring and related products, and Kanger also in its plan to venture in other business activities.

1. The company already involved in construction services.

2. In a process to acquire property for investment.

3. In a process to acquire a company which involved in a construction material trading.

4. And of course a plan for Covid-19 vaccine business, they just in the process of trying to secure the said business. It's true to say that the most critical aspect to get is the approval of Sinopharm vaccine in Malaysia by the government/NPRA. Waiting for August 2021 and hope for a clearer picture concerning the approval of the Sinopharm Covid-19 Vaccine by NPRA.

3. A Conditional Sale Agreement (SSA) between Kanger and Vendors, relating to the proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master.

Progress of the agreement:

a) Based on an announcement at BURSA dated 26 April 2021.
- The company proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master for a purchase consideration of RM94,789,436.00.
- The Purchase Consideration shall be satisfied via a combination of cash payment of RM51,999,999.62 whilst the remaining purchase consideration of RM42,789,436.38 shall be satisfied via the issuance of 713,157,273 new ordinary shares of Kanger at the issue price of RM0.06 per Kanger Share.

b) Based on an announcement at BURSA dated 9 July 2021.
- The company announced that the notice of EGM is called for the voting of the resolutions on the proposed acquisition of Sung Master and the proposed subscription of 769,513,179 new Kanger Shares at the subscription price of RM0.06 per subscription share by Mr. Kuah Choon Hing.
- The scheduled date of EGM is on 27 July 2021.

Remarks: This agreement is in progress and awaiting for approval from the authority’s approval and the approval from investors in incoming EGM.

Data vaksinasi sehingga 12.7.2021.

Jumlah Vaksinasi

Dos Pertama 7,840,034

Dos Kedua 3,526,676

Khairy Projects 40% Population Fully Vaccinated By End August

https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

@Lightspeed. Thanks. And I'm sorry.

@punterdanny. Semua hanya dibuat atas andaian dengan baca berita di internet saja. Saya bukan profesional dan bukan insider. Apa-apa pun TAYOR..

Report 5: 24 June 2021.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

@Lightspeed. ..... masalahnye, kau queue lah to sell, tak dapat sell... faham?
-------------
Nampak sangat, cerita yang awak kata beli simpan saham dari tahun 2019 adalah cerita yang tak logik bagi saya.

Kalau benar cerita itu, awak memang sekarang menyesal kerana tak jual pada harga 4 - 6 sen dahulu. Sabarlah, bukan semua keputusan yang kita buat dalam saham betul....

@Lightspeed. Macam mana tak mahu promote. Ada orang naysayer/hater yang hari-hari buat cerita yang buruk yang sebahagiannya tak betul pun faktanya.

Saya masih terperangkap di dalam.
Takkan saya nak ikut kutuk sama saham yang saya kepentingan saham di dalamnya.
Macam mana pun saya kena bertahan. Bagi maklumat sekadar saya ada untuk menepis naysayer/hater.

Walau macam mana pun, analisis berita yang saya dapat atau kongsi, ianya terhad. Dalam banyak keadaan, andaian saya juga salah. Tapi kita kena ingat. andaian penganalisis profesional pun boleh salah.

@zzzzzzz. ozura insiderkah
-----------
Frankly, setahu saya Ozura tidak masuk dalam BOD. Sepatutnya kalau saham dia banyak, di boleh adjust untuk masuk ke adalam BOD. Itu pun berdasarkan pengamatan saya sahaja. Kalau wakil Ozura ada dalam BOD, setiap urus niaga saham kena announce. Mungkin itu sebab Ozura tidak letakkan wakil dia dalam BOD.

zzzzzzz Yang saya kalao company ada projek dan MOU banyak million projek tak kan taoke besar lari ticket punya taoke besar bukan bodohlah .
------------
Betul. Tapi kita kena tengok juga sejarah Ozura. Ianya bekas kreditor. Dia bukan convert saham ICPS untuk jadi pelabur, tetapi untuk dapat duit hutang dia balik saja dengan keuntungan sekali.

Saya nak tengok nanti, fasal ICPS oleh BOD Hj Mazru. Dia jual atau simpan....

6. A Head of Agreement between Kanger and Constellation Holdings Ltd, Dubai regarding the setting up of medical examination gloves manufacturing operations in Malaysia.

Progress of the agreement:


a) Based on an announcement at BURSA dated 11 August 2020.

- The company has received a formal Expression of Interest letter (“EOI”) dated 9 August 2020 from Constellation Holdings Limited, Dubai for collaboration in the setting up of medical examination gloves operations in Malaysia.

b) Based on an announcement at BURSA dated 14 August 2020.

- The company had, on 13 August 2020 entered into a heads of agreement with Constellation Holdings Limited.
- Kanger is setting up a glove manufacturing plant in Ijok, Selangor for about RM77 million.
- Kanger has incorporated a wholly-owned subsidiary, Kanger Glove Manufacturing Sdn Bhd, which will acquire around five acres in Ijok for RM6.8 million.
- Kanger Glove would spend RM70 million to build the plant and install up to eight production lines to produce medical, surgical and/or nitrile glove.

c) Based on an announcement at BURSA dated 21 August 2020.

- The Company provided additional information pursuant to the queries by BURSA.
- The company need to apply for the relevant regulatory approvals for setting up the factory.

Remarks: No further announcement or report on the progress of this medical examination gloves manufacturing operations can be retrieved by the writer yet by to date.

4. A Conditional Sale and Purchase Agreement (SPA) between Kanger Ventures Sdn Bhd and Aset Kayamas Sdn Bhd, relating to the proposed acquisition of serviced apartments located @ Genting Highlands, Bentong, Pahang.

Progress of the agreement:

a) Based on an announcement at BURSA dated 24 February 2021.
- The company announced the acquisition proposal by Kanger Ventures Sdn Bhd , a wholly-owned subsidiary of Kanger, of 126 units of proposed serviced apartments located on the 30th to 45th floors of Tower A, Antara @ Genting Highlands, Bentong, Pahang from the developer, namely Aset Kayamas Sdn Bhd for a total purchase consideration of RM142,870,000 to be satisfied entirely via cash.

b) Based on an announcement at BURSA dated 19 April 2021.
- The company announced that the listing application pursuant to the Proposals has been submitted to Bursa Malaysia Securities Berhad on 19 April 2021.

c) Based on an announcement at BURSA dated 26 April 2021.
- The company announced that the Board had on 26 April 2021 ("Price-Fixing Date") resolved to fix the issue price of the Rights Shares at RM0.06 per Rights Share .

d) Based on an announcement at BURSA dated 2 June 2021.
- The company announced that the Bursa Securities vide its letter dated 2 June 2021, resolved to approved the following:-
i. Admission to the Official List and listing and quotation of up to 2,861,936,149 Warrants B to be issued pursuant to the Proposed Rights Issue with Warrants;

ii. Listing and quotation of:-
Up to 2,861,936,149 new Kanger Shares to be issued pursuant to the Proposed Rights Issue with Warrants; and

Remarks: This agreement in progress and awaiting for the completion of the proposed Right Issue (RI) with warrants exercises.

5. A Collaboration Agreement between Kanger Ventures and Multiple Novation, relating to a multiple constructions works.

Progress of the agreement:

a) Based on an announcement at BURSA dated 15 January 2021

The Board of Directors of Kanger International wishes to announce that its wholly-owned subsidiary, Kanger Ventures Sdn Bhd, had on 15 January 2021 entered into the following Collaboration Agreements.

a) Qbeez Holdings Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 6th July 2018 for construction of main building works of the project of development of three (3) blocks of affordable apartment on Lot 52957, Jalan Desa, Taman Desa, Mukim Kuala Lumpur, Wilayah Persekutuan (“Qbeez Project 1”);

b) Qbeez Holdings Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 28th December 2018 for construction of building and external works for the project of development two (2) blocks apartment on PT 15659, Jalan Indrahana 3, Mukim Petaling, Kuala Lumpur, Wilayah Persekutuan (“Qbeez Project 2”);

c) Lead Pinnacle Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 28th October 2019 for construction of piling and foundation works of the project of construction of a temporary gallery on PT 23923, (H.S.(D) 18603) Genting Highlands, Mukim Bentong, Daerah Bentong, Negeri Pahang (“Lead Project 1”);

d) Lead Pinnacle Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 7th July 2020 for construction of foundation and main building works for the project of a mixed development of two (2) blocks of service apartment on PT 23923, (H.S.(D) 18603) Genting Highlands, Mukim Bentong, Daerah Bentong, Negeri Pahang (“Lead Project 2”);

e) Deseo Engineering Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 13th April 2018 for construction of main building works for the project of a development of two (2) blocks of affordable apartments and two (2) blocks of apartment on Lot 55121, Jalan Jujur, Bandar Tun Razak, Cheras, Kuala Lumpur (“Deseo Project”);

f) Enduring Power Sdn Bhd and Kanger Ventures in respect of Letter of Award dated 1st June 2019 for construction of main building works for the project of a development of two (2) blocks of service apartment on Lot 1351 & 1377, Jalan Padang/Jalan Padang Walter Grenier dan sebahagian simpanan Jalan, Seksyen 67, Bukit Bintang, Bandar Kuala Lumpur (“Enduring Project”).

- Any approval required from the relevant authority and shareholders in a general meeting of the Company to undertake this collaboration herein contemplated;
- The Parties shall fulfill the above conditions within 90 (ninety) days from the date of these agreements or such extended date as shall be mutually agreed in writing by the Parties (Cut-Off Date).

Remarks: No further announcement on the progress of this Collaboration Agreement yet by to date.

@wistlebower


The Current Status of MOUs and Agreements Relating To KANGER (0170)

Started from August 2020, Kanger (0170) has signed several Memorandum of Understandings (MOUs) and agreement with several parties to start several business opportunities. The current status of the MOUs and agreements are as follows:

1. A Collaboration Agreement between Vegetta Champion Sdn. Bhd. and Kanger Ventures Sdn. Bhd. a wholly owned subsidiary of Kanger, relating to a Genting Highland construction project contract with contract value RM478 million.

Progress of the agreement:

a) Based on an announcement at BURSA dated 2 March 2021.
- VCSB received a Letter of Intent dated 2 March 2021, whereby VCSB was appointed as the
main contractor for foundation and main building works of a project.
- Kanger Ventures shall be responsible for the entire project management, financial and entire administration of the Project

b) Based on an announcement at BURSA dated 4 March 2021.
- The Company announced that the Project is expected to commence in June 2021 and to be completed in 48 Months.

Remarks: The construction project contract under this agreement will start in June 2021.

2. MOUs between Kanger and several parties, relating to the company’s efforts to secure as a distributor for Sinopharm Covid-19 vaccines in Malaysia.

Progress of the MOUs:
- The progress of the referred MOUs can be referred to an article at a web link https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-05-29-story-h1565953920-Kanger_017_The_Bamboo_Flooring_And_Related_Products_Company_Is_Trying_H.jsp

Remarks: These MOUs is in progress and awaiting for NPRA’s approval for the Sinopharm Covid-19 vaccines before Kanger probably can execute the deal to import and distribute the vaccines in Malaysia.

3. A Conditional Sale Agreement (SSA) between Kanger and Vendors, relating to the proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master.

Progress of the agreement:

a) Based on an announcement at BURSA dated 26 April 2021.
- The company proposed acquisition of 1,020,000 ordinary shares of Sung Master, representing 51.0% equity interest of Sung Master for a purchase consideration of RM94,789,436.00.
- The Purchase Consideration shall be satisfied via a combination of cash payment of RM51,999,999.62 whilst the remaining purchase consideration of RM42,789,436.38 shall be satisfied via the issuance of 713,157,273 new ordinary shares of Kanger at the issue price of RM0.06 per Kanger Share.

b) Based on an announcement at BURSA dated 12 May 2021.
- The company announced that the listing application for the Proposals has been submitted to Bursa Malaysia Securities Berhad on 12 May 2021.

Remarks: This agreement is in progress and awaiting for approval from the authority’s approval and the completion of the proposed Right Issue (RI) with warrants exercises.

zzzzzzz Kalao dapat ni projek mana dapat wang .pelaburlah .jangan tipu lagi cara sama bukimmmmmm nanti icps lagi semua ozura untung sama bod

---------------
Tunggu saja berita dari company. Kita semua tak tau apa diaorang akan buat. Kita bukan insider yang dapat curi maklumat dari syarikat.

@Lightspeed. Below is you July 11,2021 post.

Stock: [NEXGRAM]: NEXGRAM HOLDINGS BHD

Jul 11, 2021 11:08 AM | Report Abuse

I'm holding this Nexgram since 2019.. All this while I just read all the comments.. So I decided to create an account to let you know, if your intention is good, it's fine with me.. But if all of you guys try to manipulate new investors, just stop the bloody nonsense ok.. Don't embarrass yourself to be the bad guy. Especially DrWarrant the pariah
-----------------------------

You said that you hold Nexgram since 2019. I think if your entry price for 2019 should be around 1 sen - 2 sen only. I think you are still on profit if you can sell @ 2.5 - 3 sen right now.

Why don't you sell the unit when the price was around 4 - 6 sen???
What kind of investor are you??????

Be rational and don't blame others for your own dumb decisions.

@Lightspeed. Bodoh sombong punya orang akan tetap jadi bodoh sombong.

@Lightspeed....... proposed sahaja.. bukan dah dapat beli and confirm..

------------
Tolong baca progress MOU di bawah. Tolong jangan jadi pelabur yang BODOH SOMBONG. Pandai mengata orang menipu, Diri sendiri tipu orang lain dengan maklumat yang tak betul, tanpa ingin tahu apa cerita sebenarnya...

7. A Memorandum of Understanding (MOU) between Nexgram Biomedic Sdn Bhd, a wholly owned subsidiary of Nexgram with Perbadanan Kemajuan Negeri Melaka, relating to the proposed sale and purchase of a piece of land in Melaka intended for development of Melaka Lifecare Specialist Project.

The progress of the MOU:

a) Based on an announcement at BURSA dated 2 April 2021.
- Indirect wholly owned subsidiary company, Nexgram Biomedic Sdn Bhd has on 1 April 2021, digitally signed an understanding with Perbadanan Kemajuan Negeri Melaka for the proposed sale and purchase of a piece of land situated in PT 8839 Mukim Bukit Baru, District of Melaka Tengah, State of Melaka measuring an area of approximately 24.78 acres.
- The proposed acquisition of the Said Land is proposed to be developed as Melaka Lifecare Specialist Project with the proposed gross development value estimated at RM1.6 billion.
- The proposed acquisition of the land will be dedicated for mix development comprising hospital building, service SOHO (annexed to the Hospital), Wellness Centre & Bioscience Research Centre, Retirement & Medical Tourism (annexed to the Wellness Centre), MM2H Program (annexed to the Wellness Centre), 3 Star Hotel & Condotel, and Commercial and Recreation Park.
- The Proposed Sale and Purchase of the Said Land shall subject to the Parties entering a definitive agreement on the terms and conditions to be agreed mutually by the parties.
- Full details of the Proposed Land Acquisition as well as the detail of the Melaka LifeCare Specialist Project as per Chapter 10 of the ACE Market Listing Requirements will be disclosed upon the signing of the definitive agreement.
- Further announcement in relation to the Proposed Sale and Purchase will be made in due course, once the details of the terms and conditions have been finalised.

b) Based on an announcement at BURSA dated 6 July 2021.
- Board of Directors of NEXGRAM is pleased to announce that NEXGRAM BIOMEDIC SDN BHD (“NBSB” OR “PURCHASER”) had on 1 July 2021 entered into a Sale and Purchase Agreement (“SPA”) with PERBADANAN KEMAJUAN NEGERI MELAKA (“PKNM” OR “VENDOR”) to acquire a piece of 99 years of leasehold land held under PT 8839, Mukim Bukit Baru, District of Melaka Tengah, State of Melaka with measuring an area of approximately 10.031 hectares (equivalent to 24.78 acres) (“the said Land”) with a purchase consideration of Ringgit Malaysia Sixty One Million Five Hundred Twenty Six Thousand Seven Hundred Fifty Seven and Sen Sixty (RM61,526,757.60) only (“the Purchase Price”) calculated at the rate of Ringgit Malaysia Fifty Seven (RM57.00) only per square foot (“Proposed Land Acquisition”).
- The Proposed Land Acquisition shall be satisfied in cash by internal generated funds, financing and/or any future corporate exercise which will be announced in due course.

c. Based on an announcement at BURSA dated 12 July 2021.
- The Board of Directors of Nexgram announce the additional information as required in Query by BURSA.

Remark:
1. The said SPA to acquire the land is subject to, the company:
(i) appoint an Adviser,
(ii) issue a circular which includes the information set out in Appendix 10B to its shareholders;
(iii) seek shareholders’ approval of the transaction in a general meeting.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3174702

Ada ke mungkin syarikat yang nak delisted mempunyai plan macam ni?

Minta tolong fikirlah wahai OKU_2020 a.k.a MDP.. He He

Khairy Projects 40% Population Fully Vaccinated By End August

Report 5: 24 June 2021.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be some companies who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

The outstanding balance of PP shares unsubscribed is 346,827,550.

Under the agreement, Sinopharm Group has appointed KIB as the SOLE DISTRIBUTOR for the vaccines, medical devices and products in Malaysia.

Source: https://www.msn.com/en-my/news/national/kanger-sinopharm-inks-agreement-for-covid-19-vaccine-distribution-in-malaysia/ar-BB19x0Lr

1. Perjanjian sebagai DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107

2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE

Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia. Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes. The first batch of vaccines is expected to arrive in Malaysia on May 2021).


3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE

Sumber:

1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

..... WAITING FOR THE PROBABLE SINOPHARM COVID-19 VACCINE APPROVAL IN AUGUST FROM THE GOVERNMENT/NPRA.

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.